IBRX

IMMUNITYBIO INC

IBRX·45256X103·US·Common Stock·Healthcare - Biotechnology-Activist

IBRX (IMMUNITYBIO INC) is held by 154 institutional investors as of Q1 2026. Largest holders: BlackRock, Inc. ($202.1M), STATE STREET CORP ($135.8M), VANGUARD PORTFOLIO MANAGEMENT LLC ($125.2M). Net institutional sentiment: Bullish.

154
Holders
(15 Elite)
$1.2B
Total Value
71% (165)
Consensus
117 buying - 48 selling
13F: Insider & Congress:
IBRXSmart Money Verdict
View all
Held by 154 funds
15 elite
Who's Trading
InsiderSCSelecky ChristobelSell $9KJun 30, 2026
InsiderSCSelecky ChristobelSell $862KJun 29, 2026
ActivistCECambridge Equities, LP25.5%Feb 25, 2026
InsiderSJSimon Barry J.Sell $901KFeb 24, 2026
InsiderSJSimon Barry J.Sell $1.7MFeb 23, 2026
InsiderSCSelecky ChristobelSell $250KFeb 23, 2026
InsiderSJSimon Barry J.Sell $93KFeb 20, 2026
InsiderSJSimon Barry J.Sell $503KJan 20, 2026
InsiderSJSimon Barry J.Sell $591KJan 20, 2026
InsiderSCSelecky ChristobelSell $188KJan 20, 2026
Fund
Action
Shares
Value
Weight
Est. P&L
Conviction
Increased
26.3M(+2.9%)$202.1M0.0%+201.31%
31
Increased
17.7M(+7.6%)$135.8M0.0%+112.94%
33
New
16.3M$125.2M0.0%-17.80%
42
New
15.1M$116M0.0%-17.80%
42
New
12.6M$96.4M0.1%-17.80%
41
Increased
8M(+1.4%)$61.6M0.0%+36.72%
30
Decreased
4.4M(-7.0%)$33.6M0.0%+253.08%
0
Decreased
4M(-21.3%)$30.8M0.0%+191.07%
0
Increased
3.4M(+0.0%)$26.4M0.1%+179.15%
29
Decreased
3.2M(-47.4%)$24.8M0.0%+290.65%
0
Increased
2.9M(+47.6%)$22.6M0.0%+57.28%
39
New
2.9M$22.5M0.1%-17.80%
39
Increased
2.5M(+12.3%)$19.2M0.0%+16.39%
32
Decreased
2.5M(-0.9%)$19M0.0%+37.30%
0
Increased
2.4M(+2.7%)$18.8M0.0%+205.59%
29
New
2.1M$16.3M0.0%-17.80%
39
Decreased
1.9M(-22.7%)$14.5M0.0%+231.91%
0
Increased
1.6M(+923.5%)$12.6M0.1%-11.12%
45
Increased
1.5M(+1731.8%)$11.4M0.0%-14.39%
45
Increased
1.4M(+1099.3%)$10.9M0.0%-12.18%
45

Showing 1-20 of 167

1 / 9

Other Healthcare stocks held by institutions

Data sourced from four SEC data sources: 13F, Form 4, 13D/13G, and STOCK Act. Not financial advice. Full disclaimer

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used